Skin Cutaneous Melanoma: Mutation Analysis (MutSig v1.5)
(WT cohort)
Maintained by Dan DiCara (Broad Institute)
Overview
Introduction

This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v1.5 was used to generate the results found in this report.

- Working with individual set: SKCM-WT

- Number of patients in set: 34

Input

The input for this pipeline is a set of individuals with the following files associated for each:

1. An annotated .maf file describing the mutations called for the respective individual, and their properties.

2. A .wig file that contains information about the coverage of the sample.

Summary

- MAF used for this analysis:SKCM-WT.final_analysis_set.maf

- Significantly mutated genes (q ≤ 0.1): 2

- Mutations seen in COSMIC: 53

- Significantly mutated genes in COSMIC territory: 5

- Genes with clustered mutations (≤ 3 aa apart): 156

- Significantly mutated genesets: 0

- Significantly mutated genesets: (excluding sig. mutated genes):0

Mutation Preprocessing

- Read 34 MAFs of type "Broad"

- Total number of mutations in input MAFs: 19965

- After removing 101 blacklisted mutations: 19864

- After removing 334 noncoding mutations: 19530

Mutation Filtering

- Number of mutations before filtering: 19530

- After removing 261 mutations outside gene set: 19269

- After removing 23 mutations outside category set: 19246

- After removing 4 "impossible" mutations in

- gene-patient-category bins of zero coverage: 18958

Results
Breakdown of Mutations by Type

Table 1. Get Full Table Table representing breakdown of mutations by type.

type | count
--- | ---
Frame_Shift_Del | 104
Frame_Shift_Ins | 31
In_Frame_Del | 22
In_Frame_Ins | 9
Missense_Mutation | 11627
Nonsense_Mutation | 695
Nonstop_Mutation | 5
Silent | 6564
Splice_Site | 182
Translation_Start_Site | 7
Total | 19246

Breakdown of Mutation Rates by Category Type

Table 2. Get Full Table A breakdown of mutation rates per category discovered for this individual set.

category | n | N | rate | rate_per_mb | relative_rate | exp_ns_s_ratio
--- | --- | --- | --- | --- | --- | ---
(C/T)p*C->T | 8682 | 266510991 | 0.000033 | 33 | 2.5 | 1.6
(A/G)p*C->T | 995 | 223586921 | 4.5e-06 | 4.5 | 0.34 | 1.9
A->G | 532 | 473016329 | 1.1e-06 | 1.1 | 0.085 | 2.3
transver | 1422 | 963114241 | 1.5e-06 | 1.5 | 0.11 | 5
indel+null | 1030 | 963114241 | 1.1e-06 | 1.1 | 0.081 | NaN
double_null | 18 | 963114241 | 1.9e-08 | 0.019 | 0.0014 | NaN
Total | 12679 | 963114241 | 0.000013 | 13 | 1 | 3.5

Target Coverage for Each Individual

The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).

Figure 1.

Distribution of Mutation Counts, Coverage, and Mutation Rates Across Samples

Figure 2. Patients counts and rates file used to generate this plot: SKCM-WT.patients.counts_and_rates.txt

CoMut Plot

Figure 3. Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.

Significantly Mutated Genes

Column Descriptions:

- N = number of sequenced bases in this gene across the individual set

- n = number of (nonsilent) mutations in this gene across the individual set

- npat = number of patients (individuals) with at least one nonsilent mutation

- nsite = number of unique sites having a non-silent mutation

- nsil = number of silent mutations in this gene across the individual set

- n1 = number of nonsilent mutations of type: (C/T)p*C->T

- n2 = number of nonsilent mutations of type: (A/G)p*C->T

- n3 = number of nonsilent mutations of type: A->G

- n4 = number of nonsilent mutations of type: transver

- n5 = number of nonsilent mutations of type: indel+null

- n6 = number of nonsilent mutations of type: double_null

- p_ns_s = p-value for the observed nonsilent/silent ratio being elevated in this gene

- p = p-value (overall)

- q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Table 3. Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 2. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).

rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | SERPINI2 | serpin peptidase inhibitor, clade I (pancpin), member 2 | 41024 | 5 | 5 | 5 | 0 | 3 | 0 | 1 | 1 | 0 | 0 | 0.18 | 4.4e-06 | 0.042
2 | RAC1 | ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) | 20840 | 5 | 5 | 4 | 0 | 4 | 0 | 0 | 1 | 0 | 0 | 0.11 | 4.6e-06 | 0.042
3 | ESRP1 | epithelial splicing regulatory protein 1 | 71635 | 6 | 6 | 6 | 0 | 2 | 0 | 0 | 3 | 1 | 0 | 0.16 | 0.000023 | 0.11
4 | PLCB4 | phospholipase C, beta 4 | 118270 | 9 | 6 | 8 | 0 | 5 | 0 | 1 | 1 | 2 | 0 | 0.046 | 0.000037 | 0.11
5 | TUBA1B | tubulin, alpha 1b | 44856 | 4 | 4 | 3 | 0 | 1 | 0 | 0 | 3 | 0 | 0 | 0.33 | 0.000041 | 0.11
6 | MUC7 | mucin 7, secreted | 38240 | 6 | 5 | 5 | 0 | 4 | 0 | 2 | 0 | 0 | 0 | 0.083 | 0.000042 | 0.11
7 | TAF1A | TATA box binding protein (TBP)-associated factor, RNA polymerase I, A, 48kDa | 47345 | 4 | 4 | 3 | 0 | 1 | 0 | 0 | 3 | 0 | 0 | 0.46 | 0.000044 | 0.11
8 | KRTAP5-1 | keratin associated protein 5-1 | 28538 | 4 | 4 | 4 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 0.46 | 0.000049 | 0.11
9 | CYLC1 | cylicin, basic protein of sperm head cytoskeleton 1 | 28932 | 4 | 4 | 4 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0.59 | 0.000058 | 0.12
10 | CLCC1 | chloride channel CLIC-like 1 | 57643 | 4 | 4 | 4 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0.52 | 0.000064 | 0.12
11 | CTNND2 | catenin (cadherin-associated protein), delta 2 (neural plakophilin-related arm-repeat protein) | 113745 | 11 | 8 | 10 | 0 | 7 | 0 | 0 | 3 | 1 | 0 | 0.0098 | 0.000072 | 0.12
12 | OR6N1 | olfactory receptor, family 6, subfamily N, member 1 | 31310 | 3 | 3 | 3 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0.39 | 0.000088 | 0.13
13 | OR51M1 | olfactory receptor, family 51, subfamily M, member 1 | 31569 | 5 | 4 | 5 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 0.14 | 0.0001 | 0.14
14 | PCDHB5 | protocadherin beta 5 | 81328 | 6 | 5 | 6 | 1 | 4 | 0 | 0 | 1 | 1 | 0 | 0.17 | 0.00011 | 0.15
15 | PSG6 | pregnancy specific beta-1-glycoprotein 6 | 44166 | 6 | 4 | 6 | 1 | 4 | 1 | 1 | 0 | 0 | 0 | 0.2 | 0.00018 | 0.22
16 | COLEC10 | collectin sub-family member 10 (C-type lectin) | 24585 | 3 | 3 | 3 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0.37 | 0.00027 | 0.31
17 | FLG2 | filaggrin family member 2 | 243668 | 10 | 8 | 10 | 1 | 7 | 0 | 2 | 1 | 0 | 0 | 0.23 | 0.00029 | 0.31
18 | KLHL13 | kelch-like 13 (Drosophila) | 65039 | 6 | 5 | 6 | 1 | 5 | 0 | 1 | 0 | 0 | 0 | 0.28 | 0.00033 | 0.32
19 | UGT3A1 | UDP glycosyltransferase 3 family, polypeptide A1 | 53473 | 6 | 4 | 6 | 1 | 3 | 0 | 0 | 2 | 1 | 0 | 0.33 | 0.00034 | 0.32
20 | PLXDC2 | plexin domain containing 2 | 46175 | 5 | 4 | 5 | 1 | 4 | 0 | 1 | 0 | 0 | 0 | 0.35 | 0.00037 | 0.33
21 | IDH1 | isocitrate dehydrogenase 1 (NADP+), soluble | 42629 | 3 | 3 | 2 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0.34 | 0.00041 | 0.33
22 | CASS4 | Cas scaffolding protein family member 4 | 78974 | 6 | 4 | 6 | 1 | 2 | 0 | 2 | 2 | 0 | 0 | 0.31 | 0.00041 | 0.33
23 | NTRK1 | neurotrophic tyrosine kinase, receptor, type 1 | 67001 | 4 | 4 | 4 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0.6 | 0.00043 | 0.33
24 | GNA11 | guanine nucleotide binding protein (G protein), alpha 11 (Gq class) | 33844 | 3 | 3 | 2 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0.31 | 0.00046 | 0.34
25 | ADAMTS9 | ADAM metallopeptidase with thrombospondin type 1 motif, 9 | 202507 | 9 | 7 | 8 | 0 | 3 | 0 | 2 | 3 | 1 | 0 | 0.062 | 0.0005 | 0.36
26 | PTPN14 | protein tyrosine phosphatase, non-receptor type 14 | 122571 | 6 | 6 | 6 | 0 | 3 | 0 | 1 | 1 | 1 | 0 | 0.091 | 0.0006 | 0.39
27 | LIPA | lipase A, lysosomal acid, cholesterol esterase (Wolman disease) | 41633 | 3 | 3 | 3 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0.39 | 0.00067 | 0.39
28 | CDH6 | cadherin 6, type 2, K-cadherin (fetal kidney) | 79373 | 7 | 5 | 7 | 1 | 5 | 0 | 1 | 0 | 1 | 0 | 0.16 | 0.00068 | 0.39
29 | SI | sucrase-isomaltase (alpha-glucosidase) | 167528 | 8 | 6 | 7 | 1 | 5 | 3 | 0 | 0 | 0 | 0 | 0.34 | 0.00068 | 0.39
30 | ODF1 | outer dense fiber of sperm tails 1 | 25820 | 3 | 3 | 3 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0.29 | 0.0007 | 0.39
31 | USH1C | Usher syndrome 1C (autosomal recessive, severe) | 85057 | 4 | 4 | 4 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 0.34 | 0.00071 | 0.39
32 | CHODL | chondrolectin | 24839 | 4 | 4 | 4 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 0.33 | 0.00075 | 0.39
33 | NDUFS7 | NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa (NADH-coenzyme Q reductase) | 13929 | 2 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0.55 | 0.00076 | 0.39
34 | CCNE2 | cyclin E2 | 42806 | 3 | 3 | 2 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0.84 | 0.00077 | 0.39
35 | NPY5R | neuropeptide Y receptor Y5 | 45610 | 4 | 4 | 4 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0.34 | 0.00077 | 0.39

SERPINI2

Figure S1. This figure depicts the distribution of mutations and mutation types across the SERPINI2 significant gene.

RAC1

Figure S2. This figure depicts the distribution of mutations and mutation types across the RAC1 significant gene.

COSMIC analyses

In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.

Table 4. Get Full Table Significantly mutated genes (COSMIC territory only). To access the database please go to: COSMIC. Number of significant genes found: 5. Number of genes displayed: 10

rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | IDH1 | isocitrate dehydrogenase 1 (NADP+), soluble | 3 | 5 | 3 | 170 | 4476 | 1.8e-09 | 8.3e-06
2 | LGR6 | leucine-rich repeat-containing G protein-coupled receptor 6 | 5 | 4 | 2 | 136 | 2 | 1.6e-06 | 0.0028
3 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 3 | 52 | 3 | 1768 | 14972 | 2.1e-06 | 0.0028
4 | EPHA4 | EPH receptor A4 | 3 | 5 | 2 | 170 | 2 | 2.5e-06 | 0.0028
5 | KIT | v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog | 4 | 240 | 4 | 8160 | 606 | 5.1e-06 | 0.0046
6 | ARHGDIG | Rho GDP dissociation inhibitor (GDI) gamma | 1 | 1 | 1 | 34 | 1 | 0.00045 | 0.17
7 | ARNT | aryl hydrocarbon receptor nuclear translocator | 1 | 1 | 1 | 34 | 1 | 0.00045 | 0.17
8 | CACNB2 | calcium channel, voltage-dependent, beta 2 subunit | 2 | 1 | 1 | 34 | 1 | 0.00045 | 0.17
9 | LRRC4C | leucine rich repeat containing 4C | 4 | 1 | 1 | 34 | 1 | 0.00045 | 0.17
10 | MSTN | myostatin | 2 | 1 | 1 | 34 | 1 | 0.00045 | 0.17

Note:

n - number of (nonsilent) mutations in this gene across the individual set.

cos = number of unique mutated sites in this gene in COSMIC

n_cos = overlap between n and cos.

N_cos = number of individuals times cos.

cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.

p = p-value for seeing the observed amount of overlap in this gene)

q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Clustered Mutations

Table 5. Get Full Table Genes with Clustered Mutations

num | gene | desc | n | mindist | nmuts0 | nmuts3 | nmuts12 | npairs0 | npairs3 | npairs12
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
2750 | IDH1 | isocitrate dehydrogenase 1 (NADP+), soluble | 3 | 0 | 3 | 3 | 3 | 3 | 3 | 3
6123 | TMC5 | transmembrane channel-like 5 | 6 | 0 | 3 | 3 | 3 | 3 | 3 | 3
3730 | MUC16 | mucin 16, cell surface associated | 73 | 0 | 2 | 2 | 4 | 2 | 2 | 4
3840 | NBPF9 | neuroblastoma breakpoint family, member 9 | 6 | 0 | 2 | 2 | 4 | 2 | 2 | 4
2273 | GABRA6 | gamma-aminobutyric acid (GABA) A receptor, alpha 6 | 5 | 0 | 1 | 3 | 3 | 1 | 3 | 3
4375 | PAPPA2 | pappalysin 2 | 9 | 0 | 1 | 2 | 2 | 1 | 2 | 2
169 | ADH1B | alcohol dehydrogenase 1B (class I), beta polypeptide | 4 | 0 | 1 | 1 | 3 | 1 | 1 | 3
704 | C15orf2 | chromosome 15 open reading frame 2 | 16 | 0 | 1 | 1 | 3 | 1 | 1 | 3
1 | A1CF | APOBEC1 complementation factor | 4 | 0 | 1 | 1 | 2 | 1 | 1 | 2
3874 | NEBL | nebulette | 6 | 0 | 1 | 1 | 2 | 1 | 1 | 2

Note:

n - number of mutations in this gene in the individual set.

mindist - distance (in aa) between closest pair of mutations in this gene

npairs3 - how many pairs of mutations are within 3 aa of each other.

npairs12 - how many pairs of mutations are within 12 aa of each other.

Geneset Analyses

Table 6. Get Full Table A Ranked List of Significantly Mutated Genesets. (Source: MSigDB GSEA Cannonical Pathway Set).Number of significant genesets found: 0. Number of genesets displayed: 10

rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | SA_G1_AND_S_PHASES | Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. | ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 | 15 | CDKN2A(2), E2F1(1), PRB1(5), TP53(2) | 422815 | 10 | 6 | 10 | 3 | 4 | 0 | 1 | 1 | 4 | 0 | 0.34 | 0.0015 | 0.92
2 | ACTINYPATHWAY | The Arp 2/3 complex localizes to the Y-junction of polymerizing actin fibers that enable lamellipod extension and consequent cell motility. | ABI-2, ACTA1, ACTR2, ACTR3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, NCK1, NCKAP1, NTRK1, PIR, PSMA7, RAC1, WASF1, WASF2, WASF3, WASL | 18 | ARPC1B(3), NCKAP1(1), NTRK1(4), RAC1(5) | 752925 | 13 | 12 | 12 | 2 | 7 | 0 | 2 | 3 | 1 | 0 | 0.15 | 0.0075 | 1
3 | ARFPATHWAY | Cyclin-dependent kinase inhibitor 2A is a tumor suppressor that induces G1 arrest and can activate the p53 pathway, leading to G2/M arrest. | ABL1, CDKN2A, E2F1, MDM2, MYC, PIK3CA, PIK3R1, POLR1A, POLR1B, POLR1C, POLR1D, RAC1, RB1, TBX2, TP53, TWIST1 | 16 | CDKN2A(2), E2F1(1), POLR1A(2), POLR1B(1), RAC1(5), RB1(1), TP53(2) | 1001094 | 14 | 11 | 13 | 3 | 7 | 0 | 1 | 2 | 4 | 0 | 0.16 | 0.0089 | 1
4 | SALMONELLAPATHWAY | Salmonella induces membrane ruffling in infected cells via bacterial proteins including SipA, SipC, and SopE, which alter actin structure. | ACTA1, ACTR2, ACTR3, ARPC1A, ARPC1B, ARPC2, ARPC3, ARPC4, CDC42, RAC1, WASF1, WASL | 12 | ARPC1B(3), RAC1(5) | 400383 | 8 | 8 | 7 | 1 | 6 | 0 | 1 | 1 | 0 | 0 | 0.15 | 0.018 | 1
5 | TERTPATHWAY | hTERC, the RNA subunit of telomerase, and hTERT, the catalytic protein subunit, are required for telomerase activity and are overexpressed in many cancers. | HDAC1, MAX, MYC, SP1, SP3, TP53, WT1, ZNF42 | 7 | SP1(2), TP53(2) | 351795 | 4 | 4 | 4 | 1 | 0 | 0 | 2 | 1 | 1 | 0 | 0.69 | 0.025 | 1
6 | SELENOAMINO_ACID_METABOLISM |  | AHCY, CBS, CTH, GGT1, MARS, MARS2, MAT1A, MAT2B, PAPSS1, PAPSS2, SCLY, SEPHS1 | 12 | AHCY(1), MARS(3), MAT1A(2), PAPSS1(1), PAPSS2(3), SCLY(1) | 615278 | 11 | 7 | 11 | 2 | 7 | 2 | 0 | 1 | 1 | 0 | 0.077 | 0.055 | 1
7 | SA_REG_CASCADE_OF_CYCLIN_EXPR | Expression of cyclins regulates progression through the cell cycle by activating cyclin-dependent kinases. | CCNA1, CCNA2, CCND1, CCNE1, CCNE2, CDK2, CDK4, CDKN1B, CDKN2A, E2F1, E2F2, E2F4, PRB1 | 13 | CCNE1(1), CCNE2(3), CDKN2A(2), E2F1(1), PRB1(5) | 448780 | 12 | 8 | 11 | 3 | 5 | 0 | 0 | 4 | 3 | 0 | 0.27 | 0.055 | 1
8 | CAPROLACTAM_DEGRADATION |  | AKR1A1, ECHS1, EHHADH, HADHA, SDS | 5 | AKR1A1(1), EHHADH(2), HADHA(2), SDS(1) | 240462 | 6 | 5 | 6 | 0 | 5 | 0 | 0 | 0 | 1 | 0 | 0.044 | 0.065 | 1
9 | ACE_INHIBITOR_PATHWAY_PHARMGKB |  | ACE, AGT, AGTR1, AGTR2, BDKRB2, KNG1, NOS3, REN | 8 | ACE(2), AGTR1(2), AGTR2(1), BDKRB2(3), KNG1(1), NOS3(3), REN(2) | 489373 | 14 | 8 | 14 | 4 | 6 | 0 | 1 | 4 | 3 | 0 | 0.13 | 0.072 | 1
10 | CIRCADIANPATHWAY | A heterodimer composed of Bmal1 and Clock acts as a transcription factor for proteins that regulate circadian rhythms, such as Per and Cry. | ARNTL, CLOCK, CRY1, CRY2, CSNK1E, PER1 | 6 | CLOCK(2), CRY1(2), PER1(1) | 417978 | 5 | 4 | 4 | 0 | 1 | 1 | 0 | 1 | 2 | 0 | 0.35 | 0.082 | 1

Table 7. Get Full Table A Ranked List of Significantly Mutated Genesets (Excluding Significantly Mutated Genes). Number of significant genesets found: 0. Number of genesets displayed: 10

rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | SA_G1_AND_S_PHASES | Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. | ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 | 15 | CDKN2A(2), E2F1(1), PRB1(5), TP53(2) | 422815 | 10 | 6 | 10 | 3 | 4 | 0 | 1 | 1 | 4 | 0 | 0.34 | 0.0015 | 0.92
2 | TERTPATHWAY | hTERC, the RNA subunit of telomerase, and hTERT, the catalytic protein subunit, are required for telomerase activity and are overexpressed in many cancers. | HDAC1, MAX, MYC, SP1, SP3, TP53, WT1, ZNF42 | 7 | SP1(2), TP53(2) | 351795 | 4 | 4 | 4 | 1 | 0 | 0 | 2 | 1 | 1 | 0 | 0.69 | 0.025 | 1
3 | SELENOAMINO_ACID_METABOLISM |  | AHCY, CBS, CTH, GGT1, MARS, MARS2, MAT1A, MAT2B, PAPSS1, PAPSS2, SCLY, SEPHS1 | 12 | AHCY(1), MARS(3), MAT1A(2), PAPSS1(1), PAPSS2(3), SCLY(1) | 615278 | 11 | 7 | 11 | 2 | 7 | 2 | 0 | 1 | 1 | 0 | 0.077 | 0.055 | 1
4 | SA_REG_CASCADE_OF_CYCLIN_EXPR | Expression of cyclins regulates progression through the cell cycle by activating cyclin-dependent kinases. | CCNA1, CCNA2, CCND1, CCNE1, CCNE2, CDK2, CDK4, CDKN1B, CDKN2A, E2F1, E2F2, E2F4, PRB1 | 13 | CCNE1(1), CCNE2(3), CDKN2A(2), E2F1(1), PRB1(5) | 448780 | 12 | 8 | 11 | 3 | 5 | 0 | 0 | 4 | 3 | 0 | 0.27 | 0.055 | 1
5 | CAPROLACTAM_DEGRADATION |  | AKR1A1, ECHS1, EHHADH, HADHA, SDS | 5 | AKR1A1(1), EHHADH(2), HADHA(2), SDS(1) | 240462 | 6 | 5 | 6 | 0 | 5 | 0 | 0 | 0 | 1 | 0 | 0.044 | 0.065 | 1
6 | ACE_INHIBITOR_PATHWAY_PHARMGKB |  | ACE, AGT, AGTR1, AGTR2, BDKRB2, KNG1, NOS3, REN | 8 | ACE(2), AGTR1(2), AGTR2(1), BDKRB2(3), KNG1(1), NOS3(3), REN(2) | 489373 | 14 | 8 | 14 | 4 | 6 | 0 | 1 | 4 | 3 | 0 | 0.13 | 0.072 | 1
7 | CIRCADIANPATHWAY | A heterodimer composed of Bmal1 and Clock acts as a transcription factor for proteins that regulate circadian rhythms, such as Per and Cry. | ARNTL, CLOCK, CRY1, CRY2, CSNK1E, PER1 | 6 | CLOCK(2), CRY1(2), PER1(1) | 417978 | 5 | 4 | 4 | 0 | 1 | 1 | 0 | 1 | 2 | 0 | 0.35 | 0.082 | 1
8 | NICOTINATE_AND_NICOTINAMIDE_METABOLISM |  | AOX1, CD38, ENPP1, ENPP3, NADSYN1, NMNAT1, NMNAT2, NNMT, NNT, NP, NT5C, NT5E, NT5M, QPRT | 13 | AOX1(3), CD38(2), ENPP1(1), ENPP3(1), NADSYN1(2), NNMT(1), NT5E(1), QPRT(1) | 714118 | 12 | 7 | 12 | 2 | 7 | 1 | 0 | 2 | 2 | 0 | 0.13 | 0.084 | 1
9 | FXRPATHWAY | The nuclear receptor transcription factors FXR and LXR are activated by cholesterol metabolites and regulate cholesterol homeostasis. | FABP6, LDLR, NR0B2, NR1H3, NR1H4, RXRA | 6 | LDLR(3), NR1H4(2), RXRA(1) | 270174 | 6 | 4 | 6 | 1 | 3 | 2 | 1 | 0 | 0 | 0 | 0.17 | 0.087 | 1
10 | HSA00643_STYRENE_DEGRADATION | Genes involved in styrene degradation | FAH, GSTZ1, HGD | 3 | FAH(1), HGD(2) | 111602 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0.75 | 0.093 | 1

Methods & Data
Methods

In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

- Analysis Results (MD5 checksum)

- Auxiliary Data (MD5 checksum)

- MAGE-TAB File (MD5 checksum)

References
[1] TCGA, Integrated genomic analyses of ovarian carcinoma, Nature 474:609 - 615 (2011)
Copyright © 2013 Broad Institute TCGA GDAC as part of the TCGA Research Network. All rights reserved.
Made with Nozzle